Patents Assigned to Adherex Technologies, Inc.
-
Patent number: 8658618Abstract: Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme in both nervous and non-nervous tissues within the patient and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU generated from a prodrug is in substantial excess of DPD inhibitor in the patient.Type: GrantFiled: October 14, 2010Date of Patent: February 25, 2014Assignee: Adherex Technologies, Inc.Inventor: Thomas Spector
-
Patent number: 8318756Abstract: Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU prodrug is in substantial excess of DPD inhibitor in the patient.Type: GrantFiled: December 5, 2005Date of Patent: November 27, 2012Assignee: Adherex Technologies, Inc.Inventors: Thomas Spector, William Paul Peters, Donald W. Kufe, Brian Huber
-
Publication number: 20120022083Abstract: Compounds, particularly compounds having activity as modulators of cadherin-mediated cell adhesion having the following structure: or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R1, R2, R3, R4, R5, R6, A, X, Y, Z, m and n are as defined herein. Methods associated with preparation and use of the same, as well as pharmaceutical compositions containing the same, are also disclosed.Type: ApplicationFiled: February 9, 2011Publication date: January 26, 2012Applicant: ADHEREX TECHNOLOGIES, INC.Inventors: Mukur Gupta, Brian Huber, Orest W. Blaschuk
-
Publication number: 20110130359Abstract: Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme in both nervous and non-nervous tissues within the patient and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU generated from a prodrug is in substantial excess of DPD inhibitor in the patient.Type: ApplicationFiled: October 14, 2010Publication date: June 2, 2011Applicant: ADHEREX TECHNOLOGIES, INC.Inventor: Thomas Spector
-
Publication number: 20090291967Abstract: Compounds, particularly compounds having activity as modulators of cadherin-mediated cell adhesion having the following structure: or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R1, R2, R3, R4, R5, R6, A, X, Y, Z, m and n are as defined herein. Methods associated with preparation and use of the same, as well as pharmaceutical compositions containing the same, are also disclosed.Type: ApplicationFiled: March 5, 2009Publication date: November 26, 2009Applicant: ADHEREX TECHNOLOGIES, INC.Inventors: Mukur Gupta, Brian Huber, Orest W. Blaschuk
-
Publication number: 20090196833Abstract: Topical formulations comprising inhibitors of dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP) and/or uridine phosphorylase (UP) enzyme inhibitors are provided for the treatment of hand-foot syndrome (HFS) in cancer patients undergoing treatment with 5-FU and 5-FU prodrugs.Type: ApplicationFiled: February 6, 2009Publication date: August 6, 2009Applicant: ADHEREX TECHNOLOGIES INC.Inventors: William Paul Peters, Mukur Gupta
-
Publication number: 20090131306Abstract: Chemically modified cyclic peptides comprising cell adhesion recognition (CAR) sequences are provided having improved properties, such as improved stability. Also provided are methods of making and using same.Type: ApplicationFiled: June 13, 2008Publication date: May 21, 2009Applicant: ADHEREX TECHNOLOGIES, INC.Inventors: Mukur Gupta, Brian Huber, William Paul Peters
-
Patent number: 7481999Abstract: Compositions and methods for modulating OB-cadherin-mediated functions are provided. The compositions and methods employ OB-cadherin modulating agents which generally comprise one or more of: (a) a peptide sequence that is at least 50% identical to an OB-cadherin CAR sequence; (b) a non-peptide mimetic of an OB-cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds an OB-cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises an OB-cadherin CAR sequence or analogue thereof.Type: GrantFiled: December 3, 2004Date of Patent: January 27, 2009Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, Barbara J. Gour, James Matthew Symonds, Stephen Byers
-
Patent number: 7476509Abstract: Modulating agents and methods for enhancing or inhibiting nonclassical cadherin-mediated functions, such as atypical or desmosomal cadherin-mediated functions, are provided. The modulating agents comprise at least a tryptophan-containing cell adhesion recognition sequence of an atypical and/or desmosomal cadherin, a conservative analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, pharmaceutically active substance and/or support material.Type: GrantFiled: November 14, 2003Date of Patent: January 13, 2009Assignee: Adherex Technologies Inc.Inventors: Orest W Blaschuk, Stephanie D Michaud
-
Patent number: 7456153Abstract: Modulating agents and methods for enhancing or inhibiting classical cadherin-mediated functions are provided. The modulating agents comprise at least a tryptophan-containing cell adhesion recognition sequence of a classical cadherin molecule, a conservative analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, pharmaceutically active substance and/or support material.Type: GrantFiled: November 14, 2003Date of Patent: November 25, 2008Assignee: Adherex Technologies Inc.Inventors: Orest W. Blaschuk, Stephanie D. Michaud
-
Patent number: 7446120Abstract: Peptidomimetics of cyclic peptides, and compositions comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.Type: GrantFiled: June 12, 2007Date of Patent: November 4, 2008Assignee: Adherex Technologies, Inc.Inventors: Barbara J. Gour, Orest W. Blaschuk, Anmar Ali, Feng Ni, Zhigang Chen, Stephanie D. Michaud, Shoameng Wang, Zenjian Hu
-
Publication number: 20080255168Abstract: Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU prodrug is in substantial excess of DPD inhibitor in the patient. Also provided are topical formulations comprising DPD, TP and/or UP inhibitors and methods of using same.Type: ApplicationFiled: February 6, 2008Publication date: October 16, 2008Applicant: ADHEREX TECHNOLOGIES, INC.Inventors: William Paul Peters, Mukur Gupta
-
Publication number: 20080194467Abstract: Improved methods for treating cancer which employ combinations comprising cadherin antagonists with certain anticancer agents or treatments are provided. The methods of the invention involve the administration of cadherin antagonist before, concurrent with, or after, administration of an anticancer agent or treatment and provide unexpectedly improved therapeutic benefit in the treatment of tumors growing in vivo.Type: ApplicationFiled: September 27, 2007Publication date: August 14, 2008Applicants: ADHEREX TECHNOLOGIES, INC., DEPARTMENT OF VETERANS AFFAIRSInventors: William Paul Peters, Brian Huber, Douglas Scott Tyler
-
Publication number: 20080081831Abstract: Peptidomimetics of cyclic peptides, and compositions comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.Type: ApplicationFiled: June 12, 2007Publication date: April 3, 2008Applicant: ADHEREX TECHNOLOGIES, INC.Inventors: Barbara Gour, Orest Blaschuk, Anmar Ali, Feng Ni, Zhigang Chen, Stephanie Michaud, Shoameng Wang, Zenjian Hu
-
Patent number: 7268115Abstract: Peptidomimetics of cyclic peptides, and compositions comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.Type: GrantFiled: April 10, 2003Date of Patent: September 11, 2007Assignee: Adherex Technologies, Inc.Inventors: Barbara J. Gour, Orest W. Blaschuk, Anmar Ali, Feng Ni, Zhigang Chen, Stephanie Denise Michaud, Shaomeng Wang, Zenjian Hu
-
Publication number: 20070203057Abstract: Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a motif. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.Type: ApplicationFiled: December 27, 2006Publication date: August 30, 2007Applicant: ADHEREX TECHNOLOGIES, INC.Inventors: Patrick Doherty, Orest Blaschuk, Barbara Gour
-
Patent number: 7122623Abstract: Cyclic peptides comprising a cadherin cell adhesion recognition sequence HAV, and compositions comprising such cyclic peptides, are provided. Methods for using such peptides for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.Type: GrantFiled: August 1, 2003Date of Patent: October 17, 2006Assignee: Adherex Technologies, Inc.Inventor: Orest W Blaschuk
-
Publication number: 20060183884Abstract: Cyclic peptides comprising a cadherin cell adhesion recognition sequence HAV, and compositions comprising such cyclic peptides, are provided. Methods for using such peptides for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.Type: ApplicationFiled: December 9, 2005Publication date: August 17, 2006Applicant: Adherex Technologies, Inc.Inventors: Orest Blaschuk, Barbara Gour, Riaz Farookhi, Anmar Ali, Sarah George
-
Publication number: 20060148753Abstract: Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU prodrug is in substantial excess of DPD inhibitor in the patient.Type: ApplicationFiled: December 5, 2005Publication date: July 6, 2006Applicant: Adherex Technologies, Inc.Inventors: Thomas Spector, William Peters, Donald Kufe, Brian Huber
-
Patent number: 6962969Abstract: Modulating agents for inhibiting or enhancing nonclassical cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) a peptide sequence that is at least 50% identical to a nonclassical cadherin CAR sequence; (b) a non-peptide mimetic of a nonclassical cadherin CAR sequence; (c) a substance, such as an antibody or antigen-binding fragment thereof, that specifically binds a nonclassical cadherin CAR sequence; and/or (d) a polynucleotide encoding a polypeptide that comprises a nonclassical cadherin CAR sequence or analogue thereof. Methods for using such modulating agents for modulating nonclassical cadherin-mediated cell adhesion in a variety of contexts are also provided.Type: GrantFiled: December 3, 2001Date of Patent: November 8, 2005Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour